Loading the section…

RCUS: financial statements from SEC — TradeAlmanac

RCUS

Arcus Biosciences, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Revenue	17M	26M	160M	28M	48M	39M
Research and development	122M	141M	139M	122M	123M	115M
Selling, general and administrative	29M	27M	29M	28M	30M	30M
Operating expenses	151M	168M	168M	150M	153M	145M
Operating income	−134M	−142M	−8M	−122M	−105M	−106M
Pre-tax income	−128M	−135M	0	−112M	−92M	−93M
Income tax	0	0	0	0	0	0
Net income	−128M	−135M	0	−112M	−92M	−93M
Earnings per share	−1.02	−1.27	0.00	−1.14	−1.00	−1.02
Earnings per share, diluted	−1.02	−1.27	0.00	−1.14	−1.00	−1.02
Weighted average shares	125M	107M	106M	98M	91M	91M
Weighted average shares, diluted	125M	107M	107M	98M	91M	91M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	201M	222M	238M	248M	192M	150M	201M	156M
Current assets	844M	1.01B	857M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	−138M	−132M
Depreciation and amortisation	2M	3M
Share-based compensation	19M	16M
Capital expenditure	0	1M
Investing cash flow	114M	32M
Financing cash flow	3M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator